After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor. DXCM’s stock fell nearly ...

DexCom (DXCM) is forecasting robust earnings growth of 19.2% per year and revenue growth of 11.8% per year. Both figures outpace the broader US market’s revenue growth forecast of 10.4%. Over the past ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

DexCom Inc (DXCM) reports a robust 22% increase in worldwide revenue, driven by expanded CGM access and strategic market ...

Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE ...